Division of Nephrology, Department of Internal Medicine Kyung Hee University College of Medicine, Kyung Hee University Hospital Seoul Korea.
Department of Medicine, Graduate School Kyung Hee University Seoul Korea.
J Am Heart Assoc. 2024 Mar 19;13(6):e032186. doi: 10.1161/JAHA.123.032186. Epub 2024 Mar 12.
Recently, the target systolic blood pressure (BP) <120 mm Hg was suggested in the population with chronic kidney disease. We aimed to determine the applicability of intensified BP and to assess the incidence of cardiovascular disease (CVD) in the population with chronic kidney disease.
Participants who were >20 years old and had estimated glomerular filtration rate 15 to 60 mL/min per 1.73 m during 2009 to 2011 were included from the database of Korean National Health Insurance Service and were followed up to 2018. Participants were categorized by BP as <120/80 mm Hg; 120 to 129/<80 mm Hg; 130 to 139/80 to 89 mm Hg; ≥140/90 mm Hg. The primary outcome was CVD risk and the secondary outcomes were all-cause mortality and progression to end-stage renal disease followed by subgroup analysis. Among the 45 263 adults with chronic kidney disease, 5196 CVD events were noted. In Cox regression analysis, higher BP was associated with a higher risk for CVD (hazard ratio [HR], 1.15 [95% CI, 1.12-1.19]; for trend <0.001), end-stage renal disease (HR, 1.29 [95% CI, 1.22-1.37]; for trend <0.001), and all-cause mortality (HR, 1.09 [95% CI, 1.06-1.13]; for trend <0.001) than BP <120/80 mm Hg. In subgroup analysis, the association between BP and CVD showed a different trend in participants taking antihypertensives compared with those not using antihypertensive drugs. When comparing BP-treated individuals to untreated individuals, a significant interaction in the association between BP categories and end-stage renal disease was observed.
The new intensive BP target proposed by 2021 Kidney Disease: Improving Global Outcomes should be applied to patients with chronic kidney disease in a personalized and advisory manner.
最近,慢性肾脏病患者的目标收缩压(BP)<120mmHg 被提出。我们旨在确定强化 BP 的适用性,并评估慢性肾脏病患者心血管疾病(CVD)的发生率。
从韩国国家健康保险服务数据库中选取 2009 年至 2011 年期间年龄>20 岁且估计肾小球滤过率为 15 至 60mL/min/1.73m2 的患者,并随访至 2018 年。根据 BP 将患者分为<120/80mmHg;120 至 129/<80mmHg;130 至 139/80 至 89mmHg;≥140/90mmHg。主要结局是 CVD 风险,次要结局是全因死亡率和进展为终末期肾病,并进行亚组分析。在 45263 名慢性肾脏病成人中,有 5196 例 CVD 事件。在 Cox 回归分析中,较高的 BP 与 CVD(风险比[HR],1.15[95%置信区间,1.12-1.19];趋势 P<0.001)、终末期肾病(HR,1.29[95%置信区间,1.22-1.37];趋势 P<0.001)和全因死亡率(HR,1.09[95%置信区间,1.06-1.13];趋势 P<0.001)的风险增加相关。在亚组分析中,BP 与 CVD 之间的关联在服用降压药的患者与未服用降压药的患者之间呈现出不同的趋势。当将 BP 治疗组与未治疗组进行比较时,观察到 BP 类别与终末期肾病之间关联的显著交互作用。
2021 年肾脏病:改善全球结局提出的新的强化 BP 目标应该以个性化和咨询的方式应用于慢性肾脏病患者。